Loss of the tumor suppressor PTEN is a common occurrence in prostate cancer. This aberration leads to the ectopic activation of the PI3K-Akt pathway, which promotes tumor growth. Here, we show that the transcription factor Gata3 is progressively lost in Pten-deficient mouse prostate tumors as a result of both transcriptional down-regulation and increased proteasomal degradation. To determine the significance of this loss, we used conditional loss- and gain-of-function approaches to manipulate Gata3 expression levels in prostate tumors. Our results show that Gata3 inactivation in Pten-deficient prostates accelerates tumor invasion. Conversely, enforced expression of GATA3 in Pten-deficient tissues markedly delays tumor progression. In Pten-deficient prostatic ducts, enforced GATA3 prevented Akt activation, which correlated with the down-regulation of Pik3cg and Pik3c2a mRNAs, encoding respectively class I and II PI3K subunits. Remarkably, the majority of human prostate tumors similarly show loss of active GATA3 as they progress to the aggressive castrate-resistant stage. In addition, GATA3 expression levels in hormone-sensitive tumors holds predictive value for tumor recurrence. Together, these data establish Gata3 as an important regulator of prostate cancer progression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/hmg/ddt088 | DOI Listing |
JAMA Netw Open
January 2025
Department of Epidemiology and Biostatistics, University of California, San Francisco.
Importance: Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors.
Objective: To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region.
Front Immunol
January 2025
Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Prostate-Specific Membrane Antigen (PSMA) is a highly expressed and structurally unique target specific to prostate cancer (PCa). Diagnostic and therapeutic approaches in nuclear medicine, coupling PSMA ligands with radionuclides, have shown significant clinical success. PSMA-PET/CT effectively identifies tumors and metastatic lymph nodes for imaging purposes, while -PSMA-617 (Pluvicto) has received FDA approval for treating metastatic castration-resistant PCa (mCRPC).
View Article and Find Full Text PDFCureus
December 2024
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, JPN.
Rectal gastrointestinal stromal tumors (GISTs) are often asymptomatic and may be detected as giant tumors. This may require highly invasive surgery for radical resection. Here, we describe a 74-year-old man with a locally advanced non-metastatic GIST in the right anterolateral wall of the lower rectum.
View Article and Find Full Text PDFDigit Health
January 2025
Department of Urology, General Hospital of Northern Theater Command, Shenyang, China.
Purpose: Prostate cancer (PCa) is the second most common cancer in males worldwide, requiring improvements in diagnostic imaging to identify and treat it at an early stage. Bi-parametric magnetic resonance imaging (bpMRI) is recognized as an essential diagnostic technique for PCa, providing shorter acquisition times and cost-effectiveness. Nevertheless, accurate diagnosis using bpMRI images is difficult due to the inconspicuous and diverse characteristics of malignant tumors and the intricate structure of the prostate gland.
View Article and Find Full Text PDFUrol Case Rep
January 2025
The Cancer Ecology Center, The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA.
PSMA-PET/CT has emerged as a superior diagnostic tool for prostate cancer, demonstrating enhanced accuracy over conventional imaging methods. Although sensitive for detecting local and metastatic prostate tumors, it can also identify other non-prostate PSMA positive lesions. Here, we report a rare case of a 67-year-old patient with metastatic prostate adenocarcinoma who was found to have an incidental Gastrointestinal Stromal Tumor (GIST), during restaging with 68Ga-PSMA-11 PET/CT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!